Home / Investors Information / EDAP Schedules Webcast and Conference Call for First Quarter 2013 Results Read more about EDAP Schedules Webcast and Conference Call for First Quarter 2013 Results EDAP Outlines Significant Participation at 2013 American Urological Association Annual Meeting Read more about EDAP Outlines Significant Participation at 2013 American Urological Association Annual Meeting EDAP Announces 23% First Quarter 2013 Revenue Growth Read more about EDAP Announces 23% First Quarter 2013 Revenue Growth EDAP Reports Fourth Quarter 2012 and Full Year Results Read more about EDAP Reports Fourth Quarter 2012 and Full Year Results EDAP Receives U.S. FDA Filing Acceptance of Pre-Market Approval Application Read more about EDAP Receives U.S. FDA Filing Acceptance of Pre-Market Approval Application EDAP Introduces Focal.One(R): A New Robotic HIFU Device for Focal Therapy of Prostate Cancer Read more about EDAP Introduces Focal.One(R): A New Robotic HIFU Device for Focal Therapy of Prostate Cancer EDAP Schedules Webcast and Conference Call for Fourth Quarter and Full Year 2012 Results Read more about EDAP Schedules Webcast and Conference Call for Fourth Quarter and Full Year 2012 Results EDAP Receives U.S. FDA Administrative Acceptance Review Notification for Ablatherm(R)-HIFU Pre-Market Approval Application Read more about EDAP Receives U.S. FDA Administrative Acceptance Review Notification for Ablatherm(R)-HIFU Pre-Market Approval Application EDAP's Ablatherm-HIFU Offers Reliable Therapy for Localized Prostate Cancer Read more about EDAP's Ablatherm-HIFU Offers Reliable Therapy for Localized Prostate Cancer EDAP's Ablatherm-HIFU Demonstrates Long-Term Efficacy and Safety Over Fourteen-Year Period Read more about EDAP's Ablatherm-HIFU Demonstrates Long-Term Efficacy and Safety Over Fourteen-Year Period Pagination First page « First Previous page ‹ Previous … Page 27 Page 28 Page 29 Page 30 Current page 31 Page 32 Page 33 Page 34 Page 35 … Next page Next › Last page Last » Subscribe to
EDAP Schedules Webcast and Conference Call for First Quarter 2013 Results Read more about EDAP Schedules Webcast and Conference Call for First Quarter 2013 Results
EDAP Outlines Significant Participation at 2013 American Urological Association Annual Meeting Read more about EDAP Outlines Significant Participation at 2013 American Urological Association Annual Meeting
EDAP Announces 23% First Quarter 2013 Revenue Growth Read more about EDAP Announces 23% First Quarter 2013 Revenue Growth
EDAP Reports Fourth Quarter 2012 and Full Year Results Read more about EDAP Reports Fourth Quarter 2012 and Full Year Results
EDAP Receives U.S. FDA Filing Acceptance of Pre-Market Approval Application Read more about EDAP Receives U.S. FDA Filing Acceptance of Pre-Market Approval Application
EDAP Introduces Focal.One(R): A New Robotic HIFU Device for Focal Therapy of Prostate Cancer Read more about EDAP Introduces Focal.One(R): A New Robotic HIFU Device for Focal Therapy of Prostate Cancer
EDAP Schedules Webcast and Conference Call for Fourth Quarter and Full Year 2012 Results Read more about EDAP Schedules Webcast and Conference Call for Fourth Quarter and Full Year 2012 Results
EDAP Receives U.S. FDA Administrative Acceptance Review Notification for Ablatherm(R)-HIFU Pre-Market Approval Application Read more about EDAP Receives U.S. FDA Administrative Acceptance Review Notification for Ablatherm(R)-HIFU Pre-Market Approval Application
EDAP's Ablatherm-HIFU Offers Reliable Therapy for Localized Prostate Cancer Read more about EDAP's Ablatherm-HIFU Offers Reliable Therapy for Localized Prostate Cancer
EDAP's Ablatherm-HIFU Demonstrates Long-Term Efficacy and Safety Over Fourteen-Year Period Read more about EDAP's Ablatherm-HIFU Demonstrates Long-Term Efficacy and Safety Over Fourteen-Year Period
